Helen Collins
2018
Compensation breakdown
| Non-Equity Incentive Plan | $168,960 |
|---|---|
| Option Awards | $596,380 |
| Salary | $435,000 |
| Stock Awards | $130,830 |
| Other | $6,036 |
| Total | $1,337,206 |
Collins received $596.4K in option awards, accounting for 45% of the total pay in 2018.
Collins also received $169K in non-equity incentive plan, $435K in salary, $130.8K in stock awards and $6K in other compensation.
Rankings
In 2018, Helen Collins' compensation ranked 7,731st out of 14,244 executives tracked by ExecPay. In other words, Collins earned more than 45.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 7,731 out of 14,244 | 46th |
Division Manufacturing | 3,010 out of 5,759 | 48th |
Major group Chemicals And Allied Products | 1,126 out of 2,122 | 47th |
Industry group Drugs | 950 out of 1,811 | 48th |
Industry Pharmaceutical Preparations | 740 out of 1,385 | 47th |
Pay ratio
| Helen Collins' Pay | $1,337,206 |
|---|---|
| Median Employee's Pay | $201,670 |
| Pay Ratio | 7to 1 |
In 2018, the annual total compensation of Helen Collins was $1,337,206.
The annual total compensation of the median employee at Five Prime Therapeutics was $201,670.
The ratio of Helen Collins' pay to the pay of median employee was therefore 7 to one.
Collins' colleagues
We found six more compensation records of executives who worked with Helen Collins at Five Prime Therapeutics in 2018.
2018
Aron Knickerbocker
Five Prime Therapeutics
Chief Executive Officer
2018
David Smith
Five Prime Therapeutics
Chief Financial Officer
2018
Bryan Irving
Five Prime Therapeutics
Chief Scientific Officer
2018
Francis Sarena
Five Prime Therapeutics
Secretary
2018
Linda Rubinstein
Five Prime Therapeutics
Chief Financial Officer
2018
Marc Belsky
Five Prime Therapeutics